Baiyunshan announced that Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., a holding subsidiary of the company, received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration. Amikacin sulfate injection passed the consistent evaluation of generic drug quality and efficacy, and also agreed to change the prescription process, quality standards, and packaging materials and containers in direct contact with the drug. This product was launched in 1985. In 2025, Tianxin Pharmaceutical's sales revenue for this product was 2,8251,000 yuan, and the R&D investment for this consistency evaluation was about 3.1283 million yuan. Passing the evaluation this time is conducive to improving the market competitiveness of this product, and there is a risk of uncertainty in drug sales.

Baiyunshan announced that Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., a holding subsidiary of the company, received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration. Amikacin sulfate injection passed the consistent evaluation of generic drug quality and efficacy, and also agreed to change the prescription process, quality standards, and packaging materials and containers in direct contact with the drug. This product was launched in 1985. In 2025, Tianxin Pharmaceutical's sales revenue for this product was 2,8251,000 yuan, and the R&D investment for this consistency evaluation was about 3.1283 million yuan. Passing the evaluation this time is conducive to improving the market competitiveness of this product, and there is a risk of uncertainty in drug sales.